Outcome of immediate dose optimization of infliximab in inflammatory bowel disease patients

QR kód

Outcome of immediate dose optimization of infliximab in inflammatory bowel disease patients

Elmentve itt :

Bibliográfiai részletek
Szerzők:	Bacsur Péter Farkas Klaudia Molnár Tamás
Dokumentumtípus:	Cikk
Megjelent:	2022
Sorozat:	JOURNAL OF CROHNS & COLITIS 16 No. 5
Tárgyszavak:	Klinikai orvostan
doi:	10.1093/ecco-jcc/jjab207
mtmt:	32585204
Online Access:	http://publicatio.bibl.u-szeged.hu/23314

Hasonló tételek

Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease
Szerző: Bor Renáta, et al.
Megjelent: (2017)

Switching from infliximab to biosimilar in inflammatory bowel disease
Szerző: Milassin Ágnes, et al.
Megjelent: (2019)

Post-inflammatory polyps burden as a prognostic marker of disease-outcome in patients with inflammatory bowel disease
Szerző: Ellul Pierre, et al.
Megjelent: (2023)

A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease
Szerző: Farkas Klaudia, et al.
Megjelent: (2018)

Sarcopenia as an independent predictor of the surgical outcomes of patients with inflammatory bowel disease
Szerző: Erős Adrienn, et al.
Megjelent: (2020)

Improving disease management of patients with inflammatory bowel disease the potential role of self-concordant health goals /
Szerző: Horvát Barbara, et al.
Megjelent: (2023)

Lupus-like reactions in patients with inflammatory bowel disease
Szerző: Pigniczki Daniella, et al.
Megjelent: (2019)

Importance of Diet in Inflammatory Bowel Disease – Data from the Patients’ View
Szerző: Molnár Tamás, et al.
Megjelent: (2014)

Diagnosis and outcome of extranodal primary intestinal lymphoma in inflammatory bowel disease An ECCO CONFER Case Series /
Szerző: Phillips Frank, et al.
Megjelent: (2022)

Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease An ECCO CONFER Multicentre Case Series /
Szerző: Festa Stefano, et al.
Megjelent: (2022)

Outcomes of treatment cessation afterswitching to subcutaneous vedolizumabtreatment in inflammatory bowel diseases
Szerző: Bacsur Péter, et al.
Megjelent: (2024)

Outcomes of Patients With Inflammatory Bowel Diseases Switched from Maintenance Therapy with a Biosimilar to Remicade.
Szerző: Iliás Ákos, et al.
Megjelent: (2019)

Psychological characteristics of patients with inflammatory bowel disease during the first wave of COVID-19
Szerző: Sánta Anett, et al.
Megjelent: (2023)

Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease
Szerző: Pallagi-Kunstár Éva, et al.
Megjelent: (2014)

Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease results of a multicenter survey /
Szerző: Sarlós Patrícia, et al.
Megjelent: (2023)

Spotlight on Transition in Patients With Inflammatory Bowel Disease A Systematic Review /
Szerző: Erős Adrienn, et al.
Megjelent: (2020)

Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls
Szerző: Bacsur Péter, et al.
Megjelent: (2023)

Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases a prospective; multicentre; nationwide cohort /
Szerző: Gecse Krisztina Barbara, et al.
Megjelent: (2016)

Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases results from Central European nationwide cohort /
Szerző: Bálint Anita, et al.
Megjelent: (2017)

Iron Deficiency Anemia in Inflammatory Bowel Disease What Do We Know? /
Szerző: Resál Tamás, et al.
Megjelent: (2021)

Enhancing self-management of patients with inflammatory bowel disease the role of autonomy support in health goal pursuit /
Szerző: Horvát Barbara, et al.
Megjelent: (2024)

Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases A European retrospective observational study /
Szerző: Goessens Laurent, et al.
Megjelent: (2021)

Surgery Due to Inflammatory Bowel Disease During Pregnancy Mothers and Offspring Outcomes From an Ecco Confer Multicentre Case Series (Scar Study) /
Szerző: Chaparro María, et al.
Megjelent: (2022)

Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease long-term extension data from a Phase 3 study /
Szerző: Schmidt Christoph, et al.
Megjelent: (2016)

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Szerző: Sabatine Marc S., et al.
Megjelent: (2017)

Crucial steps for treatment optimization and decision making in inflammatory bowel disease management
Szerző: Szántó Kata Judit
Megjelent: (2023)

New Promising Combo Therapy in Inflammatory Bowel Diseases Refractory to Anti-TNF Agents Cyclosporine Plus Vedolizumab /
Szerző: Szántó Kata Judit, et al.
Megjelent: (2018)

ECCO Guidelines on Inflammatory Bowel Disease and Malignancies
Szerző: Gordon Hannah, et al.
Megjelent: (2023)

Inflammatory Bowel Disease and Physical activity a study on the impact of diagnosis on the level of exercise amongst patients with IBD /
Szerző: Gatt K., et al.
Megjelent: (2019)

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
Szerző: Gönczi Lóránt, et al.
Megjelent: (2017)

Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics
Szerző: Mandel Michael D., et al.
Megjelent: (2014)

Co-Administration of Proton Pump Inhibitors May Negatively Affect the Outcome in Inflammatory Bowel Disease Treated with Vedolizumab
Szerző: Szemes Kata, et al.
Megjelent: (2024)

Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination.
Szerző: Resál Tamás, et al.
Megjelent: (2023)

Combination therapy with anti-TNFs and thiopurines does affect drug metabolite levels but it is not associated with body composition in inflammatory bowel disease patients A cross-sectional study /
Szerző: Szántó Kata Judit, et al.
Megjelent: (2021)

Does inflammatory bowel disease have different characteristics according to stage of adolescence?
Szerző: Szántó Kata Judit, et al.
Megjelent: (2021)

The use of complementary and alternative medicine is less frequent in patients with inflammatory bowel disease than in patients with other chronic gastrointestinal disorders
Szerző: Fábián Anna, et al.
Megjelent: (2018)

Steroid but not biological therapy elevates the risk of venous thromboembolic events in inflammatory bowel disease a meta-analysis /
Szerző: Sarlós Patrícia, et al.
Megjelent: (2018)

Infliximab dóziselemzés colitis ulcerosában. Infliximab dose escalation - contradiction between financing protocol and real life data
Szerző: Szántó Kata, et al.
Megjelent: (2018)

Tuberculin skin test and Quantiferon in BCG vaccinated; immunosuppressed patients with moderate-to-severe inflammatory bowel disease
Szerző: Kürti Zsuzsanna, et al.
Megjelent: (2015)

Inflammatory bowel disease does not alter the clinical features and the management of acute pancreatitis A prospective, multicentre, exact-matched cohort analysis /
Szerző: Dohos Dóra, et al.
Megjelent: (2022)